Ankündigung • May 14
Skin Elements Limited Receive Further Notice from Kingsbury Wealth Pty Ltd On May 14, 2026, Skin Elements Limited announced that it has received a further request to call a meeting of the shareholders of the Company from Kingsbury Wealth Pty Ltd to consider resolutions to remove directors from the board of the Company that an Extraordinary General Meeting of shareholders of the will be held on June 23, 2026. The Company stated that the Company’s other Directors, Peter Francis Malone and Messrs Filippo (Phil) Leone Giglia, Roderick Anthony Nicholas and Joshua Gordon, are not the subject of removal Resolutions at the Meeting. Additionally, the board recommends that shareholders vote against each of the resolutions. New Risk • Mar 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$12.0m (US$8.39m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 4.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (186% increase in shares outstanding). Revenue is less than US$1m (AU$341k revenue, or US$238k). Market cap is less than US$10m (AU$12.0m market cap, or US$8.39m). Board Change • Feb 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Company Secretary & Independent Non-Executive Director Stuart Usher was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Oct 31
Skin Elements Limited, Annual General Meeting, Nov 28, 2025 Skin Elements Limited, Annual General Meeting, Nov 28, 2025. Location: level 1, westcentre , 1260 hay street, west perth, wa 6005 Australia Ankündigung • Oct 15
Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 157,500,000
Price\Range: AUD 0.002
Discount Per Security: AUD 0.00012
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,092,500,000
Price\Range: AUD 0.002
Discount Per Security: AUD 0.00012
Transaction Features: Subsequent Direct Listing Reported Earnings • Oct 04
Full year 2025 earnings released: AU$0.002 loss per share (vs AU$0.004 loss in FY 2024) Full year 2025 results: AU$0.002 loss per share (improved from AU$0.004 loss in FY 2024). Revenue: AU$470.0k (up 13% from FY 2024). Net loss: AU$1.73m (loss narrowed 20% from FY 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 31
Full year 2025 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in FY 2024) Full year 2025 results: AU$0.003 loss per share (improved from AU$0.004 loss in FY 2024). Revenue: AU$470.0k (up 13% from FY 2024). Net loss: AU$1.73m (loss narrowed 20% from FY 2024). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Ankündigung • Mar 13
Skin Elements Limited has completed a Follow-on Equity Offering in the amount of AUD 0.643692 million. Skin Elements Limited has completed a Follow-on Equity Offering in the amount of AUD 0.643692 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 136,894,740
Price\Range: AUD 0.003
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 34,335,812
Price\Range: AUD 0.003
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 43,333,333
Price\Range: AUD 0.003
Transaction Features: Rights Offering New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 78% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-AU$1.6m). Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Revenue is less than US$1m (AU$416k revenue, or US$259k). Market cap is less than US$10m (AU$3.01m market cap, or US$1.87m). Ankündigung • Dec 21
Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.513692 million. Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.513692 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 136,894,740
Price\Range: AUD 0.003
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 34,335,812
Price\Range: AUD 0.003
Transaction Features: Rights Offering Ankündigung • Oct 30
Skin Elements Limited, Annual General Meeting, Nov 29, 2024 Skin Elements Limited, Annual General Meeting, Nov 29, 2024. Location: at 1242 hay street, west perth wa 6005 Australia Reported Earnings • Oct 04
Full year 2024 earnings released: AU$0.004 loss per share (vs AU$0.026 loss in FY 2023) Full year 2024 results: AU$0.004 loss per share (improved from AU$0.026 loss in FY 2023). Revenue: AU$416.2k (up 114% from FY 2023). Net loss: AU$2.16m (loss narrowed 81% from FY 2023). Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.003 loss per share (vs AU$0.026 loss in FY 2023) Full year 2024 results: AU$0.003 loss per share (improved from AU$0.026 loss in FY 2023). Revenue: AU$416.2k (up 114% from FY 2023). Net loss: AU$1.87m (loss narrowed 84% from FY 2023). New Risk • Mar 02
New major risk - Negative shareholders equity The company has negative equity. Total equity: -AU$287k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$810k free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-AU$287k). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (AU$183k revenue, or US$119k). Market cap is less than US$10m (AU$2.82m market cap, or US$1.84m). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding). Board Change • Oct 10
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Phil Giglia was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 05
Full year 2023 earnings released: AU$0.026 loss per share (vs AU$0.004 loss in FY 2022) Full year 2023 results: AU$0.026 loss per share (further deteriorated from AU$0.004 loss in FY 2022). Revenue: AU$194.1k (down 86% from FY 2022). Net loss: AU$11.4m (loss widened AU$9.84m from FY 2022). Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.009 loss per share (vs AU$0.004 loss in FY 2022) Full year 2023 results: AU$0.009 loss per share (further deteriorated from AU$0.004 loss in FY 2022). Net loss: AU$4.10m (loss widened 160% from FY 2022). New Risk • Aug 31
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.8m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 2.0% per year over the past 5 years. Revenue is less than US$1m (AU$1.4m revenue, or US$898k). Market cap is less than US$10m (AU$3.81m market cap, or US$2.47m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (33% increase in shares outstanding). Ankündigung • May 26
Skin Elements Limited, Annual General Meeting, Jun 27, 2023 Skin Elements Limited, Annual General Meeting, Jun 27, 2023, at 10:30 W. Australia Standard Time. Location: 1242 Hay Street, West Perth West Perth Western Australia Australia Agenda: To consider remuneration report; to consider approval of 10% placement facility; to consider re-election of Filippo Giglia as a director; to consider election of Stuart Douglas usher as a director; to consider ratification of prior issue of optionslisting rule 7.1; to consider ratification of prior issue of optionslisting rule 7.1A; to consider proposed issue of shares and options to 708 capital pty ltd for underwriting fee; to consider proposed issue of options to 708 capital pty ltd for lead manager services; and to consider other issues. Reported Earnings • Mar 03
First half 2023 earnings released: AU$0.007 loss per share (vs AU$0.003 loss in 1H 2022) First half 2023 results: AU$0.007 loss per share (further deteriorated from AU$0.003 loss in 1H 2022). Revenue: AU$96.1k (down 19% from 1H 2022). Net loss: AU$2.89m (loss widened 142% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Board Change • Jan 24
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Phil Giglia was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Jan 17
Skin Elements Limited Announces Executive Changes Skin Elements Limited announced that it has appointed Mr. Stuart Usher as a Non- Executive Director to the Board and as Company Secretary. Mr. Usher is a CPA and Chartered Company Secretary with over 25 years of extensive experience in the management and corporate affairs of public listed companies in Australian and Internationally, including as Company Director and Company Secretary for several other listed public companies. He holds an MBA from the University of Western Australia and has extensive experience across many industries focusing on Corporate & Financial Management, Strategy & Planning, Mergers & Acquisitions, and Investor Relations & Corporate Governance. Mr. Usher's experience is particularly applicable to Skin Elements as an emerging growth company, working with the Board and senior management team to support delivery of financial, operational, and strategic goals and market share as the Company transitions from research & development to commercial operations for its natural antimicrobial technology. Mr. Usher is also appointed as Company Secretary replacing Mr. Phil Giglia in this role. SKN also announced of the resignation of Mr. Lee Christensen as Non-Executive Director to focus on other projects. Ankündigung • Oct 19
Skin Elements Limited Provides Market Update Skin Elements Limited provided the following market update on its business plans including the commercialisation of its all-natural plant-based SE FormulaTM anti-microbial technology. The SE Formula Natural Revolution Skin Elements is at the forefront of this revolution with SE FormulaTM, a high performance proprietary all-natural antimicrobial technology. With global economies emerging from lockdown measures, the focus is on sustainability and environmental impact and increased knowledge and greater awareness of the effects of harmful and aggressive toxic chemical ingredients. People globally are now demanding eco-friendly and biodegradable solutions with improved efficacy and anti-bacterial properties. The SE FormulaTM is the result of more than 15 years research and development by the Skin Elements' team in the area of plant-based ingredients and antimicrobials. It is Australian made from a 100% plant-based proprietary formula that is biodegradable, vegan, non-corrosive, non-flammable and cruelty free. The product does not contain any synthetic chemicals including benzoates, benzalkonium chloride, hydrogen peroxides, quaternary ammonium compounds, bleach/chlorine compounds or other chemical ingredients. The SE FormulaTM is used in the Company's proprietary brands including Invisi-Shield SuprCuvr plant-based hospital grade disinfectant range, the Soléo Organics natural sunscreen brand, the PapayaActivs therapeutic skincare range and the Elizabeth Jane Natural Cosmetics. SuprCuvr (Log 7 /Log 3); SuprCuvr is a TGA registered hospital-grade disinfectant made from a 100% plant-based formula. Independent laboratory tests have confirmed that SuprCuvr has achieved very high effectiveness (99.99999% or 7 log reduction) against COVID 19 and other germs. SuprCuvr is also approved by NASAA as a Certified Organic input which confirms the products use around humans and certified organic food. Skin Elements is ready to play an active role in helping global communities to recover, survive and thrive. With Australia now emerging from COVID-19, SuprCuvr has been positioned as a high performance broad spectrum disinfectant that is safe to use with humans, animals and plants. Furthermore, Skin Elements is providing SuprCuvr at (Log 3 or 99.9%) effective against germs making SuprCuvr extremely price competitive compared to existing chemical disinfectant products. Expanding the SE FormulaTM Product Range; Skin Elements is actively seeking to expand the SuprCuvr product range beyond its use as a hospital-grade disinfectant and by offering new products at different price points. Testing results of SuprCuvr have also shown its ability to kill other potentially-dangerous pathogenic bacteria, including E.coli and Staph.aureus that can be present in-hospital settings, and independent laboratory tests were conducted on the anti-fungal capacity of SuprCuvr. Specifically, it was tested for efficacy against black mould (Aspergillus niger) and Candida albicans, highly prevalent sources of fungal infections in humans. Further trials are currently underway in Australia and New Zealand for treatment of livestock and crops. This positive outcome has the potential to open up new product applications in agriculture and horticulture for SuprCuvr, and the Company plans to progress these opportunities to expand the SE FormulaTM product range. Reported Earnings • Oct 02
Full year 2022 earnings released: AU$0.004 loss per share (vs AU$0.009 loss in FY 2021) Full year 2022 results: AU$0.004 loss per share (improved from AU$0.009 loss in FY 2021). Revenue: AU$1.41m (up 388% from FY 2021). Net loss: AU$1.58m (loss narrowed 48% from FY 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Reported Earnings • Sep 01
Full year 2022 earnings released Full year 2022 results: Revenue: AU$1.41m (up 388% from FY 2021). Net loss: AU$1.62m (loss narrowed 47% from FY 2021). Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Kevin Christensen was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Oct 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Lee Christensen was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
